Cosmos Health Inc. Form 8-K Summary
Business Context and Reporting Period
Cosmos Health Inc. (Nasdaq: COSM), a Nevada corporation headquartered in Thessaloniki, Greece, filed this Current Report on August 6, 2025, regarding events occurring on August 5, 2025. The filing details the entry into a Material Definitive Agreement for a private placement of senior secured convertible promissory notes.
Key Financial Metrics and Transaction Terms
- Total Facility Size: Maximum aggregate principal amount of $300,000,000.
- Initial Closing: $8,000,000 in principal anticipated on August 6, 2025.
- Second Closing: Up to $2,000,000 in principal subject to conditions.
- Subsequent Closings: Remaining capacity up to $290,000,000, with individual issuances not exceeding $5,000,000.
- Interest Rate: 9% per annum, payable monthly in arrears.
- Interest Payment Method: Primarily in shares of common stock ("Interest Shares"), with an option for the Company to pay in cash or a combination.
- Default Rate: Increases to 16% per annum upon an Event of Default.
- Maturity: 24 months from the respective issuance date.
- Placement Fee: 6.0% of aggregate gross proceeds paid to Curvature Securities, Inc.
- Commitment Fee: 2.0% annually on the Crypto Collateral Measurement Value.
Material Changes and Use of Proceeds
The filing represents a significant change in the Company's capital structure through the creation of a new debt facility. The net proceeds from the Note Offering are allocated as follows:
- 72.5%: Acquisition of "Note Purchased Crypto" to be held as a treasury asset on the balance sheet.
- Remaining Proceeds: General corporate purposes and working capital.
The Notes are secured by a Security and Pledge Agreement covering all personal property and assets acquired with the proceeds (the "Collateral"). An Account Control Agreement ensures the Custodian holds digital assets for the benefit of the Purchaser.
Guidance, Outlook, and Corporate Actions
The Company has agreed to call an annual meeting of stockholders within 60 days of the Initial Closing Date to approve:
- Increase in authorized capital stock to 1,500,000,000 shares of Common Stock and 300,000,000 shares of "blank check" preferred stock.
- Approval of the issuance of Conversion Shares and Notes to comply with Nasdaq Capital Market rules.
Conversion Terms: Notes are convertible into common stock at the lower of the Conversion Price or Market Price. A Beneficial Ownership Limitation restricts conversion to 4.99% of outstanding shares (expandable to 9.99% with notice).
Investor Rights: The Purchaser has a right to participate in up to 25% of future equity or equity-linked financings for three years. The Company is restricted from entering into subsequent variable rate transactions without Purchaser consent.
Risks and Contingencies: The transaction relies on Section 4(a)(2) of the Securities Act. The filing does not provide specific financial statements for the period, as this is a current report on a specific event rather than a periodic financial report.
Key Facts for Investor Verification
- Verify the satisfaction of closing conditions for the initial $8,000,000 issuance on August 6, 2025.
- Confirm the specific valuation and custody arrangements for the crypto assets to be purchased with 72.5% of proceeds.
- Monitor the upcoming stockholder meeting for approval of the increased authorized share count and Nasdaq compliance.
- Assess the dilution impact of interest payments made in stock and potential future conversions.
- Review the Security Agreement to understand the scope of assets pledged as collateral.